Privosegtor Secures EMA PRIME Designation for Optic Neuritis Treatment
Decision brief
Answer first · skim in under a minute
Privosegtor has achieved EMA PRIME designation for its investigational treatment of optic neuritis, a significant regulatory milestone that may expedite development and regulatory review. This designation highlights the unmet medical need in optic neuritis and positions the company for potential future collaborations and investments.
The European Medicines Agency granted Priority Medicines (PRIME) designation to Oculis’ investigational neuroprotective candidate Privosegtor for optic neuritis on March 31, 2026, expanding European regulatory support after a January 2026 FDA Breakthrough Therapy designation grounded in Phase 2 ACUITY data.
Contents10 sections
Key Takeaways
- EMA PRIME for Privosegtor in optic neuritis was announced March 31, 2026 via company wire.
- FDA Breakthrough Therapy for the same indication was disclosed in January 2026; orphan status exists at both EMA and FDA.
- Phase 2 ACUITY (NCT04762017) is the cited clinical support package; Phase 3 PIONEER-1 (NCT07623668) is recruiting.
- PRIME accelerates dialogue and development planning—it is not an approval to market.
What does EMA PRIME mean for Privosegtor in optic neuritis?
PRIME is EMA’s scheme for early, proactive support of medicines that may offer a major therapeutic advantage or help patients without options. Oculis said EMA awarded PRIME to Privosegtor specifically for optic neuritis, a rare sight-threatening inflammation of the optic nerve often linked to multiple sclerosis.
Details appear in the GlobeNewswire March 31, 2026 release. EMA’s public overview of the scheme is on the EMA PRIME Priority Medicines page.
Which clinical evidence underpins the optic neuritis designations?
Company materials point to the Phase 2 ACUITY trial registered as NCT04762017 on ClinicalTrials.gov. ACUITY evaluated intravenous Privosegtor (also known as OCS-05) plus steroids versus placebo plus steroids in acute demyelinating optic neuritis.
Public trial summaries describe a small randomized cohort and secondary functional and structural endpoints such as low-contrast visual acuity and retinal layer thickness. Those Phase 2 signals supported regulatory designations; they do not replace Phase 3 confirmation.
How does PRIME relate to FDA Breakthrough Therapy status?
Oculis said FDA granted Breakthrough Therapy designation for Privosegtor in optic neuritis in January 2026, before the EMA PRIME decision. The company also states orphan drug status from both EMA and FDA for optic neuritis.
Together, the designations signal that both major regulators see unmet need and preliminary promise—not that benefit–risk for marketing is settled.
What is next in the PIONEER optic neuritis program?
Registrational work sits under Oculis’ PIONEER program. The Phase 3 PIONEER-1 study is listed as NCT07623668, a randomized, double-masked, placebo-controlled trial of Privosegtor 3 mg/kg/day IV for five days plus methylprednisolone in optic neuritis, with an estimated enrollment of 210 participants.
European teams should treat PRIME as a development accelerator while watching PIONEER endpoint success, safety, and any future CHMP opinion path.
Why optic neuritis remains a high unmet-need indication
Acute optic neuritis can leave lasting visual disability even after standard corticosteroids. No approved neuroprotective therapy specifically protects optic-nerve structure and function after an acute attack, which is the gap Privosegtor aims to address as a peptoid small molecule designed to cross blood–brain and retinal barriers.
That biology claim is still investigational until Phase 3 outcomes and labeling reviews are complete.
What remains unproven after PRIME?
PRIME does not approve Privosegtor, set a price, or guarantee accelerated CHMP opinion timing. Phase 2 letter gains and imaging signals need replication in larger Phase 3 populations that include patients with and without MS.
Until PIONEER readouts and a marketing authorization application succeed, Privosegtor should be described only as an investigational optic neuritis candidate.
Related NovaPharma coverage
- LENZ Therapeutics Submits VIZZ to EMA for Presbyopia
- OST-HER2 Faces 2026 EMA Call After Survival Data
- EMA CHMP Backs Four New Medicines
Frequently Asked Questions
What is EMA PRIME designation for Privosegtor in optic neuritis?
On March 31, 2026, the European Medicines Agency granted Priority Medicines (PRIME) designation to Oculis’ Privosegtor for optic neuritis, offering enhanced early regulatory support for medicines that may address major unmet needs.
Which trial supported Privosegtor’s optic neuritis regulatory designations?
Company disclosures cite the Phase 2 ACUITY trial (NCT04762017) as supporting evidence for FDA Breakthrough Therapy and EMA PRIME, alongside orphan designations from both agencies for optic neuritis.
Is Privosegtor approved for optic neuritis in Europe?
No. Privosegtor remains investigational. PRIME is not marketing authorization. Registrational work continues in the PIONEER program, including the Phase 3 PIONEER-1 study (NCT07623668).
Primary Sources
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
